Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more

Recent & Breaking News (NDAQ:VYNE)

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

GlobeNewswire April 19, 2023

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

GlobeNewswire March 30, 2023

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

GlobeNewswire March 22, 2023

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

GlobeNewswire March 9, 2023

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire February 28, 2023

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

GlobeNewswire February 22, 2023

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

GlobeNewswire February 15, 2023

VYNE Therapeutics Announces Reverse Stock Split

GlobeNewswire February 10, 2023

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

GlobeNewswire January 9, 2023

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

GlobeNewswire December 12, 2022

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

GlobeNewswire December 7, 2022

VYNE Therapeutics to Participate in Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

GlobeNewswire December 2, 2022

VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 18, 2022

VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

GlobeNewswire November 17, 2022

VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 10, 2022

VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

GlobeNewswire August 12, 2022

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

GlobeNewswire August 10, 2022

VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

GlobeNewswire July 19, 2022

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

GlobeNewswire June 17, 2022